- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378545
Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis (HO2T or NO2T)
(Feasibility) Open Label Randomised Controlled Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis
The motivation for this study comes from a desire to improve the mortality of patients with sepsis. Oxygen is cheap, readily available and is included in current United Kingdom Emergency Department guidelines, but it may also be harmful to patients with sepsis - it is important to know if this is the case.
This study is a pilot study to also assess the feasibility of delivering a larger adequately powered study.
Study Overview
Detailed Description
Currently there is no consensus on the use of oxygen therapy in sepsis resuscitation. Uncertainty exists as to whether increasing oxygen above physiological levels (hyperoxia) or maintaining physiological oxygen concentration (normoxia) confers the most benefit to patients. By indicating whether hyperoxia is beneficial or not, the study hopes to further increase the effectiveness of sepsis resuscitation.
In patients with sepsis there are convincing, coherent pathophysiological and evidence-based justifications which support both normoxia and hyperoxia.
Why normoxia may benefit patients with sepsis: Enhanced oxidative and nitrosative stress resulting from increased formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) occurs during sepsis and is assumed to have major importance during the development of shock-related hypotension, impairment of microcirculatory perfusion, mitochondrial dysfunction, and tissue injury. It is well established that increasing the inhaled fraction of inspired oxygen (FiO2) leads to an increase in ROS production. The negative effects of hyperoxia in humans have been well demonstrated in a number of pathological conditions including stroke, myocardial infarction and some lung diseases. The pathological processes behind each of these conditions is very different from that of sepsis.
In a small observational study (88 patients) in patients with sepsis, of the hyperoxic patients, 8% died in hospital versus 6% with normoxia. Further prospective controlled trials are required. The deleterious effects of hyperoxia have also been demonstrated in a rat model.
Why hyperoxia may benefit patients with sepsis: Underlying cellular hypoxia, which may be difficult to detect, has been suggested as a major cause of morbidity and mortality in sepsis - this may be reversed or attenuated by high flow oxygen.
Hyperoxia may reverse arterial hypotension and exert anti-inflammatory and antiapoptotic properties. The beneficial effects of hyperoxia have been demonstrated in rat and pig models through increased survival and reduced inflammation.
One study in rats showed the most benefit on survival from oxygen administration when oxygen was administered in the first 4 hours of the trial, with no additional benefit beyond this time.
A further study (also in rats) demonstrated that 6 hours of oxygen per 24 hours for the first 48 hours following introduction of sepsis had the most beneficial anti-inflammatory effects.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Devon
-
Plymouth, Devon, United Kingdom, PL6 8BX
- Plymouth Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged 18 years or above.
- Diagnosed with presumed 'Sepsis'.
- Arrive at Derriford Emergency Department by ambulance.
- Provision of informed consent.
- Willing to allow their General Practitioner and consultant, if appropriate, to be notified of participation in the study.
Exclusion Criteria:
- Female participants who are pregnant
- Existing diagnosis of chronic obstructive pulmonary disease (COPD)
A primary diagnosis (or suspected diagnosis) of:
- an acute cerebral vascular event
- acute coronary syndrome
- acute pulmonary oedema
- status asthmatic
- major cardiac arrhythmia (as part of primary diagnosis)
- seizure
- drug overdose
- injury from burn or trauma
- Participants who require immediate intubation and ventilation on arrival in the Emergency Department
- Participants undergoing or have undergone cardiopulmonary resuscitation in the pre-hospital phase of their treatment.
- Current participation in another Clinical Trial of an Investigational Medicinal Product (CTIMP).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hyperoxia
Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.
The oxygen delivery device will be set to deliver oxygen at 15 litres per minute.
The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
|
On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
Other Names:
|
Active Comparator: normoxia
Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%.
If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%.
Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
|
On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Does delivery of high flow oxygen (hyperoxic oxygen therapy) compared to titrated oxygen therapy (normoxic oxygen therapy) reduce mortality at 90 days
Time Frame: 90 days
|
Adult patients with sepsis presenting to the emergency department by ambulance.
|
90 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tim Nutbeam, MBBS, University Hospital Plymouth NHS Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15/P/020
- 2015-000629-35 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on Oxygen
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Aalborg University HospitalRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...Active, not recruitingHypoxemic Respiratory Failure | Oxygen ToxicityNorway, Switzerland, Denmark
-
Aalborg University HospitalUniversity of AarhusUnknownCardiac Surgery | Cardiopulmonary Bypass | Acute Lung Injury | Hyperoxia | Oxygen ToxicityDenmark
-
Chang, Steve S., M.D.Santa Barbara Cottage HospitalCompletedPostoperative AbscessUnited States
-
Princess Margaret Hospital for ChildrenCompleted
-
Royal Brompton & Harefield NHS Foundation TrustLiverpool University Hospitals NHS Foundation Trust; National Institute for...CompletedLung; Disease, Fibroid (Chronic)United Kingdom
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands
-
Heidelberg UniversityRecruitingPulmonary Arterial Hypertension | Oxygen Deficiency | CTEPHGermany
-
Aalborg University HospitalRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...CompletedHypoxemic Respiratory Failure | Oxygen ToxicityUnited Kingdom, Denmark, Finland, Iceland, Netherlands, Norway, Switzerland
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia